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Summary
Purpose: To develop concise, patient-focussed, up to date, evidence-based, expert consensus recommendations for the management of hip
and knee osteoarthritis (OA), which are adaptable and designed to assist physicians and allied health care professionals in general and
specialist practise throughout the world.
Methods: Sixteen experts from four medical disciplines (primary care, rheumatology, orthopaedics and evidence-based medicine), two con-
tinents and six countries (USA, UK, France, Netherlands, Sweden and Canada) formed the guidelines development team. A systematic
review of existing guidelines for the management of hip and knee OA published between 1945 and January 2006 was undertaken using
the validated appraisal of guidelines research and evaluation (AGREE) instrument. A core set of management modalities was generated
based on the agreement between guidelines. Evidence before 2002 was based on a systematic review conducted by European League
Against Rheumatism and evidence after 2002 was updated using MEDLINE, EMBASE, CINAHL, AMED, the Cochrane Library and
HTA reports. The quality of evidence was evaluated, and where possible, effect size (ES), number needed to treat, relative risk or odds
ratio and cost per quality-adjusted life years gained were estimated. Consensus recommendations were produced following a Delphi
exercise and the strength of recommendation (SOR) for propositions relating to each modality was determined using a visual analogue
scale.
Results: Twenty-three treatment guidelines for the management of hip and knee OA were identiﬁed from the literature search, including six
opinion-based, ﬁve evidence-based and 12 based on both expert opinion and research evidence. Twenty out of 51 treatment modalities
addressed by these guidelines were universally recommended. ES for pain relief varied from treatment to treatment. Overall there was
no statistically signiﬁcant difference between non-pharmacological therapies [0.25, 95% conﬁdence interval (CI) 0.16, 0.34] and pharmaco-
logical therapies (ES¼ 0.39, 95% CI 0.31, 0.47). Following feedback from Osteoarthritis Research International members on the draft
guidelines and six Delphi rounds consensus was reached on 25 carefully worded recommendations. Optimal management of patients
with OA hip or knee requires a combination of non-pharmacological and pharmacological modalities of therapy. Recommendations cover
the use of 12 non-pharmacological modalities: education and self-management, regular telephone contact, referral to a physical therapist,
aerobic, muscle strengthening and water-based exercises, weight reduction, walking aids, knee braces, footwear and insoles, thermal
modalities, transcutaneous electrical nerve stimulation and acupuncture. Eight recommendations cover pharmacological modalities of
treatment including acetaminophen, cyclooxygenase-2 (COX-2) non-selective and selective oral non-steroidal anti-inﬂammatory drugs
(NSAIDs), topical NSAIDs and capsaicin, intra-articular injections of corticosteroids and hyaluronates, glucosamine and/or chondroitin
sulphate for symptom relief; glucosamine sulphate, chondroitin sulphate and diacerein for possible structure-modifying effects and the
use of opioid analgesics for the treatment of refractory pain. There are recommendations covering ﬁve surgical modalities: total joint
replacements, unicompartmental knee replacement, osteotomy and joint preserving surgical procedures; joint lavage and arthroscopic
debridement in knee OA, and joint fusion as a salvage procedure when joint replacement had failed. Strengths of recommendation and
95% CIs are provided.
Conclusion: Twenty-ﬁve carefully worded recommendations have been generated based on a critical appraisal of existing guidelines, a
systematic review of research evidence and the consensus opinions of an international, multidisciplinary group of experts. The recommen-
dations may be adapted for use in different countries or regions according to the availability of treatment modalities and SOR for each
modality of therapy. These recommendations will be revised regularly following systematic review of new research evidence as this
becomes available.
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138 W. Zhang et al.: OARSI recommendations for the management of hip and knee OAOsteoarthritis (OA) is the most common type of arthritis and (1) a critical appraisal of existing treatment guidelines4;
the major cause of chronic musculoskeletal pain andmobility
disability in elderly populationsworldwide1. Kneeandhip pain
are themajor causesof difﬁculty inwalkingandclimbingstairs
in the elderly in Europe2 and the USA3 and as many as 40%
of people over the age of 65 in the community in the United
Kingdom suffer symptoms associated with knee or hip OA2.
Treatment of OA of the knee and hip is directed towards
 Reducing joint pain and stiffness.
 Maintaining and improving joint mobility.
 Reducing physical disability and handicap.
 Improving health-related quality of life.
 Limiting the progression of joint damage.
 Educating patients about the nature of the disorder and
its management.
More than 50 modalities of non-pharmacological, phar-
macological and surgical therapy for knee and hip OA are
described in the medical literature4.
Over the years a number of National and Regional Guide-
lines have been developed to assist physicians, allied
health professionals and patients in their choice of therapy
for the management of knee and hip OA, but internationally
agreed and universally applicable guidelines for the man-
agement of these global disorders have been lacking.
In September 2005 the Osteoarthritis Research Inter-
national (OARSI) appointed an international, multidisciplin-
ary committee of experts with a remit to produce up to
date, evidence-based, globally relevant, consensus recom-
mendations for the management of knee and/or hip OA in
2007. The ﬁrst part of the work of this committee was to un-
dertake a critical appraisal of all existing evidence-based and
consensus guidelines for the treatment of knee and/or hip
OA and a systematic review of the recent research evidence.
The results of this critical appraisal and systematic review
were published recently4. This second part of the report con-
tains the current OARSI evidence-based, expert consensus
recommendations for the treatment of knee and/or hip OA.
Scope and purpose
The guidelines are intended to provide concise, patient-
focussed, up to date, evidence-based, expert consensus
recommendations for the management of hip and knee
OA, which are globally relevant.
Target users
The guidelines have been developed to provide assis-
tance to physicians and allied health care professionals
who deal with patients with OA hip and knee in both primary
and secondary (specialist) care settings. The guidelines
should also provide a helpful resource for patients with
OA hip or knee, patient representative groups and health
care funders and administrators. It is anticipated that these
OARSI international core recommendations will be modiﬁed
and adapted as appropriate for National and Regional use.
Stakeholder involvement
The guideline development committee was composed of
16 experts from four medical disciplines (primary care 2,
rheumatology 11, orthopaedics 1, and evidence-based
medicine 2) and six countries in Europe and North America
(France, Netherlands, Sweden, UK, Canada and USA).
All members of the development team participated in(2) a Delphi exercise to generate consensus recommen-
dations; and (3) an exercise to grade the strength of
recommendation (SOR) for all modalities of therapy
recommended.Rigour of developmentCRITICAL APPRAISAL OF EXISTING GUIDELINESMethodological details of the systematic literature search,
the inclusion/exclusion criteria, the quality and content as-
sessment and the data analyses of all existing guidelines
for the management of hip and/or knee OA published be-
tween 1945 and October 2005 can be found in the ﬁrst part
of this report4. The quality of the guidelineswas assessed us-
ing theAGREE instrument5 and standardised percent scores
(0e100%) for scope, stakeholder involvement, rigour, clarity,
applicability and editorial independence, as well as overall
quality, were calculated. Treatment modalities addressed
and recommended by the guidelines were summarised.
Agreement (%) was estimated and the best level of evidence
(LoE) to support each recommendation was extracted.SYSTEMATIC REVIEW OF THE MORE RECENT EVIDENCESystematic reviews of research evidence for the treat-
ment of hip and/or knee OA up to January 2002 were avail-
able from the systematic literature review undertaken by the
European League against Rheumatism (EULAR). Methodo-
logical details of the systematic literature search, the inclusion/
exclusion criteria, the quality assessments and outcome
measures (efficacy, side effects and cost-effectiveness)
for research evidence relating to the treatment of OA hip
and/or knee published between 31st January 2002 and
31st January 2006 can also be found in the ﬁrst part of
this report4. The quality of evidence was evaluated using
the Oxman and Guyatt method for systematic reviews6
and the Jadad scale for randomised controlled trials
(RCTs)7. Where possible, effect size (ES)8, number needed
to treat (NNT)9, relative risk (RR) or odds ratio (OR)10 and
cost per quality-adjusted life year (QALY) gained4 were es-
timated. Sensitivity analyses11 were undertaken to deter-
mine whether selected RCTs published after January 31st
2006 would alter any of the evidence-based conclusions
from the critical appraisal of existing guidelines and the sys-
tematic review of the recent research evidence signiﬁcantly.DELPHI EXERCISE TO GENERATE CONSENSUS
RECOMMENDATIONSConcise propositions relating to all aspects of non-phar-
macological, pharmacological and surgical treatments of
OA hip and/or knee were generated as follows.
The committee of experts was divided into three
subgroups:
 Non-pharmacological:Altman,Brandt,Croft, andDoherty.
 Pharmacological: Abramson, Bierma-Zeinstra, Douga-
dos, and Hochberg.
 Surgical:Arden,Hunter,Kwoh,Lohmander, andTugwell.
Each expert was provided with a comprehensive table of
51 potential treatment modalities together with a summary
of recommendations from the critical appraisal of existing
guidelines4 (percentage of guidelines addressing modality,
AGREE instrument score for quality5, the LoE12 and ES
139Osteoarthritis and Cartilage Vol. 16, No. 2for pain8) and a summary of the systematic analysis of the
research evidence from 2002 to 20064 (Quality scores6,7,
ES8 for pain, function and stiffness, the NNT9, the RR/
OR10 and the cost per QUALY4). A full list of references
from which the summary data had been extracted was
also provided. With the exception of the co-chairs (RM
and GN) and the lead researcher (WZ), who did not contrib-
ute to the primary generation of propositions in order to
avoid administrative bias, each committee expert was
asked to generate a comprehensive list of propositions re-
lating to modalities of treatment in the group to which they
were assigned, based on the available research evidence
and their own clinical expertise. There was no limit to the
number of propositions proposed for the initial master list.
After elimination of closely similar or overlapping proposi-
tions a master list of 110 propositions relating to 54 non-phar-
macological modalities of treatment, 37 pharmacological, 18
surgical and one combining non-pharmacological and phar-
macological modalities was circulated to all members of the
guideline development group apart from RM, GN and WZ
for acceptance or rejection. The experts were also given
the opportunity to suggest amalgamations and rewording
of individual propositions. After four rounds of the Delphi ex-
ercise in which propositions with >60% of votes were
accepted, those with <20% were rejected and those attract-
ing between 20% and 60% of votes were taken forward for
consideration following further amalgamations and minor
rewording, provisional consensus was reached on 34 prop-
ositions. These were posted on the OARSI website and pre-
sented for comments and suggestions by OARSI members
at a plenary session of the World Congress on OA in
Prague in December 2006. After further additions, amal-
gamations, minor rewording and two further Delphi rounds,
consensus was reached on accepting 25 carefully worded
propositions (Table I). All eligible members of the committee
voted at each step of the Delphi exercise.STRENGTH OF RECOMMENDATION (SOR)The SOR for each treatment proposition was based on
the opinions of the guideline development group after taking
into consideration the research evidence for efﬁcacy, safety
and cost-effectiveness of each treatment proposed, and the
clinical expertise of the members of the guideline committee
including such considerations as the experts’ experience
and perception of patient tolerance, acceptability and ad-
herence to the treatment in question and their expert knowl-
edge of any logistic issues involved in the administration of
the treatment.
Each member of the guideline development committee,
except for RM, GN and WZ, was asked to indicate their
SOR for each accepted proposition on a 0e100 mm visual
analogue scale (VAS) after being provided with
(a) the list of accepted propositions in which the level of
the research evidence for each proposition was indi-
cated (Table I) according to the evidence hierarchy12
(Table II),
(b) the results of the critical appraisal of existing
guidelines4,
(c) a summary of the systematic analysis of the research
evidence from 2002 to 2006 (Ref. 4, Table 5) includ-
ing details of quality scores, ES for pain, function
and stiffness, the NNT, the RR or OR and the cost
per QALY for each modality of treatment proposed
where these were available, and
(d) a ﬁrst draft of this manuscript.Mean and standard error of the mean (S.E.M.) for the SOR
for each proposition were calculated, with and without re-
cusals for voting on individual propositions by individual
members of the committee, where there was any possibility
of a potential conﬂict of interest, and the results were ex-
pressed as means with 95% conﬁdence limits.
OARSI recommendations
After six rounds of the Delphi exercise there was expert
consensus for 25 recommendations for the treatment of hip
and knee OA. These are summarised in Table I together
with the level of evidence (LoE) supporting them, the ES for
pain relief [ESpain 95% conﬁdence interval (CI)], the extent
of consensus (%) and the SOR (mean 2 S.E.M.) for each
proposition. The treatment propositions recommended in
Table I are grouped as general, non-pharmacological, phar-
macological and surgical without ranking the recommenda-
tions for the order in which the treatments should be offered.
General recommendations
1. Optimal management of OA requires a combina-
tion of non-pharmacological and pharmacological
modalities.
SOR: 96% (95% CI 93e99)
Combination of pharmacological and non-pharmacologi-
cal treatments is frequently employed in clinical practise
and is universally recommended in 12/12 existing guide-
lines for the management of hip and/or knee OA4. Although
there was 100% consensus and strong recommendation for
combining pharmacological and non-pharmacological ther-
apies following the Delphi exercise, this recommendation
lacks evidence from RCTs with appropriate factorial design.
It is largely based on expert opinion (LoE IV) and uncon-
trolled observations of additional beneﬁt in RCTs and
meta-analyses (MAs) of trials of non-pharmacological mo-
dalities of therapy (e.g., exercise13,14, weight reduction15,16,
and education17) where all patients were receiving pharma-
cological treatment with analgesics or non-steroidal anti-
inﬂammatory drugs (NSAIDs).
Non-pharmacological modalities of treatment
2. All patients with hip and knee OA should be given
information access and education about the objec-
tives of treatment and the importance of changes
in lifestyle, exercise, pacing of activities, weight
reduction, and other measures to unload the dam-
aged joint(s). The initial focus should be on self-
help and patient-driven treatments rather than on
passive therapies delivered by health profes-
sionals. Subsequently emphasis should be placed
on encouraging adherence to the regimen of non-
pharmacological therapy.
SOR: 97% (95% CI 95e99)
Provision of information and overall patient education
about the objectives of treatment and the importance of
changes in lifestyle, exercise, pacing of activities, weight re-
duction and other measures to unload damaged joints is
supported by two MAs17,18 (LoE Ia), but the ES for pain re-
lief is small (0.06 95% CI 0.02, 0.10)18 and RCTs with an
appropriate factorial design to assess the efﬁcacy of individ-
ual components of the education programme have not been
undertaken. Attempts to identify which components of self-
management programmes contribute most to their efﬁcacy
Table I
OARSI recommendations and research evidence
Proposition LoE ES for pain (95% CI) Frequency
recommended
in existing
guidelines
Level of
consensus (%)
SOR (%)
(95% CI)
General
1. Optimal management of OA requires a combination of non-pharma-
cological and pharmacological modalities.
IV 12/12 100 96 (93e99)
Non-pharmacological modalities of treatment
2. All patients with hip and knee OA should be given information ac-
cess and education about the objectives of treatment and the impor-
tance of changes in lifestyle, exercise, pacing of activities, weight
reduction, and other measures to unload the damaged joint(s). The ini-
tial focus should be on self-help and patient-driven treatments rather
than on passive therapies delivered by health professionals. Subse-
quently emphasis should be placed on encouraging adherence to
the regimen of non-pharmacological therapy.
Ia (education) 0.06 (0.02, 0.10) 8/8 92 97 (95e99)
IV (adherence)
3. The clinical status of patients with hip or knee OA can be improved if
patients are contacted regularly by phone.
Ia 0.12 (0.00, 0.24) 2/2 77 66 (57e75)
4. Patients with symptomatic hip and knee OA may beneﬁt from refer-
ral to a physical therapist for evaluation and instruction in appropriate
exercises to reduce pain and improve functional capacity. This evalu-
ation may result in provision of assistive devices such as canes and
walkers, as appropriate.
IV 5/5 100 89 (82e96)
5. Patients with hip and knee OA should be encouraged to undertake,
and continue to undertake, regular aerobic, muscle strengthening and
range of motion exercises. For patients with symptomatic hip OA, ex-
ercises in water can be effective.
Ia (knee) 0.52 (0.34, 0.70) aerobic 21/21 85 96 (93e99)
IV (hip) 0.32 (0.23, 0.42) strength 21/21
Ib (hip, water based) 0.25 (0.02, 0.47) water based 8/8
6. Patients with hip and knee OA, who are overweight, should be en-
couraged to lose weight and maintain their weight at a lower level.
Ia 0.13 (0.12, 0.38) 13/14 100 96 (92e100)
7. Walking aids can reduce pain in patients with hip and knee OA. Pa-
tients should be given instruction in the optimal use of a cane or crutch
in the contralateral hand. Frames or wheeled walkers are often prefer-
able for those with bilateral disease.
IV 11/11 100 90 (84e96)
8. In patients with knee OA and mild/moderate varus or valgus insta-
bility, a knee brace can reduce pain, improve stability and diminish the
risk of falling.
Ia 8/9 92 76 (69e83)
9. Every patient with hip or knee OA should receive advice concerning
appropriate footwear. In patients with knee OA insoles can reduce
pain and improve ambulation. Lateral wedged insoles can be of symp-
tomatic beneﬁt for some patients with medial tibio-femoral compart-
ment OA.
IV (footwear) 92 77 (66e88)
Ia (insole) 12/13
10. Some thermal modalities may be effective for relieving symptoms
in hip and knee OA.
Ia 0.69 (0.07, 1.45) 7/10 77 64 (60e68)
11. TENS can help with short-term pain control in some patients with
hip or knee OA.
Ia 8/10 69 58 (45e72)
12. Acupuncturemaybeof symptomatic beneﬁt inpatientswith kneeOA. Ia 0.51 (0.23, 0.79) 5/8 69 59 (47e71)
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Pharmacological modalities of treatment
13. Acetaminophen (up to 4 g/day) can be an effective initial oral
analgesic for treatment of mild to moderate pain in patients with
knee or hip OA. In the absence of an adequate response, or in the
presence of severe pain and/or inﬂammation, alternative pharmaco-
logic therapy should be considered based on relative efﬁcacy and
safety, as well as concomitant medications and co-morbidities.
Ia (knee) 0.21 (0.02, 0.41) 16/16 77 92 (88e99)
IV (hip)
14. In patients with symptomatic hip or knee OA, non-steroidal anti-in-
ﬂammatory drugs (NSAIDs) should be used at the lowest effective
dose but their long-term use should be avoided if possible. In patients
with increased GI risk, either a COX-2 selective agent or a non-selec-
tive NSAID with co-prescription of a PPI or misoprostol for gastropro-
tection may be considered, but NSAIDs, including both non-selective
and COX-2 selective agents, should be used with caution in patients
with CV risk factors.
Ia (knee) 0.32 (0.24, 0.39) NSAIDþPPI 8/8 100 93 (88e99)
Ia (hip) NSAIDþmisopr-
ostol 8/8
COX-2 inhibitors
11/11
15. Topical NSAIDs and capsaicin can be effective as adjunctives and
alternatives to oral analgesic/anti-inﬂammatory agents in knee OA.
Ia (NSAIDs) 0.41 (0.22, 0.59) 7/9 100 85 (75e95)
Ia (capsaicin) 8/9
16. IA injections with corticosteroids can be used in the treatment of
hip or knee OA, and should be considered particularly when patients
have moderate to severe pain not responding satisfactorily to oral an-
algesic/anti-inﬂammatory agents and in patients with symptomatic
knee OA with effusions or other physical signs of local inﬂammation.
Ib (hip) 0.72 (0.42, 1.02) 11/13 69 78 (61e95)
Ia (knee)
17. Injections of IA hyaluronate may be useful in patients with knee or
hip OA. They are characterised by delayed onset, but prolonged dura-
tion, of symptomatic beneﬁt when compared to IA injections of
corticosteroids.
Ia (knee) 0.32 (0.17, 0.47) 8/9 85 64 (43e85)
Ia (hip)
18. Treatment with glucosamine and/or chondroitin sulphate may pro-
vide symptomatic beneﬁt in patients with knee OA. If no response is
apparent within 6 months treatment should be discontinued.
Ia (glucosamine) 0.45 (0.04, 0.86) 6/10 92 63 (44e82)
Ia (chondroitin) 0.30 (0.10, 0.70) 2/7
19. In patients with symptomatic knee OA glucosamine sulphate and
chondroitin sulphate may have structure-modifying effects while diac-
erein may have structure-modifying effects in patients with symptom-
atic OA of the hip.
Ib (knee) 69 41 (20e62)
Ib (hip)
20. The use of weak opioids and narcotic analgesics can be consid-
ered for the treatment of refractory pain in patients with hip or knee
OA, where other pharmacological agents have been ineffective, or
are contraindicated. Stronger opioids should only be used for the man-
agement of severe pain in exceptional circumstances. Non-pharmaco-
logical therapies should be continued in such patients and surgical
treatments should be considered.
Ia (week opioids) 9/9 92 82 (74e90)
IV (strong opioids)
IV (others)
Surgical modalities of treatment
21. Patients with hip or knee OA who are not obtaining adequate pain
relief and functional improvement from a combination of non-pharma-
cological and pharmacological treatment should be considered for
joint replacement surgery. Replacement arthroplasties are effective,
and cost-effective interventions for patients with signiﬁcant symptoms,
and/or functional limitations associated with a reduced health-related
quality of life, despite conservative therapy.
III 14/14 92 96 (94e98)
(continued on next page)
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Table II
Level of Evidence (LoE)
LoE Type of evidence
Ia Metaanalysis of Randomized Controlled Trials
Ib At least one Randomized Controlled Trial
IIa At least one well-designed controlled study, but
without randomisation
IIb At least one well-designed quasi-experimental study
III At least one non-experimental descriptive study
(e.g., comparative, correlation or caseecontrolled study)
IV Expert committee reports, opinions and/or experience of
respected authorities
142 W. Zhang et al.: OARSI recommendations for the management of hip and knee OAby meta-regression analysis were unsuccessful18e20. The
recommendation that initial focus should be on self-help
and patient-driven treatments rather than on passive thera-
pies delivered by health professionals is based on expert
opinion, common sense and economic considerations
alone (LoE IV). There is, however, evidence from a number
of RCTs of exercise therapy21e25 (LoE Ib) to support the
recommendation that subsequent emphasis should be
placed on encouraging adherence to the regimen of non-
pharmacological therapy.
3. The clinical status of patients with hip or knee OA
can be improved if patients are contacted regularly
by phone.
SOR: 66% (95% CI 57e75)
The best evidence to suggest that monthly telephone
contact by lay personnel aimed at promoting self-care for
patients with OA knee could be associated with improve-
ments in joint pain and physical function for up to a year
comes from an RCT in 439 OA patients26. Subsequent sub-
group analysis showed that regular telephone contact was
associated with pain relief (ES¼ 0.65, P< 0.01) even in
a small group of 40 patients whose medical treatment
with drugs and physical therapy remained stable27, and
telephone contact did not inﬂuence psycho-social outcomes
such as morale, satisfaction with care, adherence to medi-
cation or social support28. Overall the ES for pain relief and
maintenance of physical function may be much smaller.
While there are no published MAs of trials of telephone in-
tervention alone, Warsi’s MA of arthritis self-management
programmes17 included three trials in patients with knee
OA in which telephone contact was part of the pack-
age21,29,30. Notwithstanding the difﬁculty of assessing the ef-
ﬁcacy of individual components of the self-management
strategy, two of these studies29,30 demonstrated much
smaller, non-signiﬁcant, effects on pain. The estimated ES4
for the three trials was similar to the pooled ES for pain relief
in 17 self-management programmes (ES¼ 0.12, 95% CI
0.00e0.24)17. The proposition that the clinical status of pa-
tients with hip OA can be improved if patients are contacted
regularly by phone is based on expert opinion alone (LoE IV).
4. Patients with symptomatic hip and knee OA may
beneﬁt from referral to a physical therapist for eval-
uation and instruction in appropriate exercises to
reduce pain and improve functional capacity. This
evaluation may result in provision of assistive
devices such as canes and walkers, as appropriate.
SOR: 89% (95% CI 82e96)
The recommendation to refer patients with symptomatic
hip or knee OA to a physical therapist is mainly supported
by expert opinion (LoE IV). Referral to a physical therapist
143Osteoarthritis and Cartilage Vol. 16, No. 2was strongly recommended by 100% of the expert panel
and is also recommended in 5/5 of existing guidelines
where referral for physiotherapy was considered4. The rec-
ommendation to refer patients with symptomatic knee OA
for physical therapy is supported by the results of three
RCTs31e33. One demonstrated signiﬁcant short-term (8
weeks) improvements in pain, physical function and
health-related quality of life31. Another showed improve-
ments in WOMAC indices up to 1 year after referral for
a 4 week treatment programme by a physical therapist32;
and a third demonstrated improved clinical outcomes over
and above a programme of home exercises33 (LoE Ib).
However two other RCTs of multimodal physiotherapy pro-
grammes, including patellar taping and exercises, showed
no persistent beneﬁts when compared with standard treat-
ment without physical therapy34 or simulated placebo phys-
ical therapy treatment modalities35. There are no published
RCTs of referral of patients with symptomatic hip OA for
multimodal physical therapy.
5. Patients with hip and knee OA should be encour-
aged to undertake, and continue to undertake, reg-
ular aerobic, muscle strengthening and range of
motion exercises. For patients with symptomatic
hip OA, exercises in water can be effective.
SOR: 96% (95% CI 93e99)
The recommendation that patients with OA knee should
be encouraged to undertake regular aerobic walking exer-
cises and home-based quadriceps muscle strengthening
exercises is a core recommendation in 21/21 published
guidelines4 and is supported by a systematic review and
MA of 13 RCTs14 (LoE Ia). Pooled ESs for pain relief are
in the moderate range for both aerobic (ES¼ 0.52, 95%
CI 0.34, 0.70) and muscle strengthening exercises
(ES¼ 0.32, 95% CI 0.23, 0.42) and pooled ESs for self-
reported disability are 0.46 (95% CI 0.25, 0.67) for aerobic
exercise and 0.32 (95% CI 0.23, 0.41) for quadriceps
strengthening exercises. By contrast the recommendation
that patients with hip OA continue to undertake regular aer-
obic, muscle strengthening and range of motion exercises is
largely based on clinical expertise (LoE IV)36. Evidence for
pain relief (ES¼ 0.25, 95% CI 0.02, 0.47)37 and improve-
ment in stiffness (ES¼ 0.17, 95% CI 0.05, 0.39)37 in pa-
tients with symptomatic hip OA following exercise in water
comes from two RCTs37,38 (LoE Ib).
6. Patients with hip and knee OA, who are over-
weight, should be encouraged to lose weight and
maintain their weight at a lower level.
SOR: 96% (95% CI 92e100)
Encouragement to lose weight and maintain weight at
a lower level in overweight patients with lower limb OA
was strongly recommended by all members of the guideline
development group (100% Table I) and is a core recom-
mendation in 13/14 existing guidelines for the management
of lower limb OA where this modality of therapy was consid-
ered4. At the time of completing the systematic review of
the published research evidence before 31st January
2006 the recommendation was supported by the results
of two high quality RCTs15,16 (LoE Ib). In patients with
knee OA the ESs for relief of pain (ES¼ 0.13, 95% CI
0.12, 0.38)15,16, stiffness (0.36 95% CI 0.08, 0.80)15
and functional improvement (0.69 95% CI 0.24, 1.14)15
were small to moderate with an NNT of 3 (95% CI 2, 9)15for a decrease in WOMAC scores of >50%, 8 weeks after
commencing a low energy diet (3.4 MJ/day). The recom-
mendation is further supported by the publication of a recent
systematic review and MA39 of four RCTs with data on 454
patients with OA knee (LoE Ia). The pooled ESs for im-
provements in pain and physical disability are conﬁrmed
as small (0.20 95% CI 0, 0.39 and 0.23 95% CI 0.04,
0.42, respectively), with a mean weight reduction of
6.1 kg (range 4.7e7.6 kg). Meta-regression analysis dem-
onstrated signiﬁcant improvement in disability with weight
loss> 5% or at a rate of >0.24%/week. There are no pub-
lished RCTs to conﬁrm comparable beneﬁts from weight
loss in patients with hip OA. The recommendation that pa-
tients with hip OA should be encouraged to lose weight and
maintain their weight at a lower level is based on expert
opinion (LoE IV) and evidence of a relationship between
obesity and hip OA in caseecontrol studies40.
7. Walking aids can reduce pain in patients with hip
and knee OA. Patients should be given instruction
in the optimal use of a cane or crutch in the contra-
lateral hand. Frames or wheeled walkers are often
preferable for those with bilateral disease.
SOR: 90% (95% CI 84e96)
Although there are no RCTs to support their use there
was complete expert consensus for the proposition that
walking aids can reduce pain in patients with hip and
knee OA (LoE IV), and for the recommendation that patients
should be given instruction in the optimal use of a cane or
crutch in the contralateral hand. This is supported by kine-
matic studies of knee moments of force following the use
of a cane in the contralateral hand in patients with knee
OA41, and earlier studies of the biomechanics of the hip fol-
lowing the use of a stick in the contralateral hand in patients
with hip OA42.There are data that show that up to 40% of
patients with hip or knee OA own a cane43 and sticks or
canes are recommended for patients with symptomatic
knee OA in 11/11 existing guidelines4.
8. In patients with knee OA and mild/moderate varus
or valgus instability, a knee brace can reduce pain,
improve stability and diminish the risk of falling.
SOR: 76% (95% CI 69e83)
Evidence that pain, stiffness and physical function are
signiﬁcantly improved using the Western Ontario and
McMaster Universities Osteoarthritis Index (WOMAC) and
the McMaster Toronto arthritis patient preference question-
naire (MACTAR) with knee braces in patients with knee OA
comes from a Cochrane review44 (LoE Ia) and a single
RCT45 which compared the use of a valgus braceþmedical
treatment with a neoprene sleeveþmedical treatment and
medical treatment alone. Assessment at 6 months showed
greater improvement in WOMAC scores with use of the val-
gus brace than the neoprene sleeve. Knee braces are rec-
ommended in 8/9 existing guidelines for the management of
knee OA where this modality of treatment was considered4.
9. Every patient with hip or knee OA should receive
advice concerning appropriate footwear. In pa-
tients with knee OA insoles can reduce pain and
improve ambulation. Lateral wedged insoles can
be of symptomatic beneﬁt for some patients with
medial tibio-femoral compartment OA.
SOR: 77% (95% CI 66e88)
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tibio-femoral compartment OA is recommended in 12/13 ex-
isting guidelines for the management of knee OA4. The
proposition that lateral wedged insoles can provide symp-
tomatic beneﬁt for patients with medial tibio-femoral com-
partment OA, as well as decreasing lateral thrust in the
knee46, is supported by three observational studies46e48,
but not by three RCTs49e51. Despite the fact that there
was no symptomatic beneﬁt (WOMAC pain, joint stiffness,
and physical functioning subscales) at 6 months50 or 2
years51 in a prospective RCT of laterally wedged insoles
in 156 patients with medial femoro-tibial OA, NSAID usage
was reduced and compliance was better in the treatment
group. This was accepted by the investigators50,51 and
a systematic review44 as evidence supporting clinical bene-
ﬁt (LoE Ia). No structural protection was observed in this
study after 2 years51. The recommendation that every pa-
tient with hip or knee OA should receive advice concerning
appropriate footwear is based on expert opinion alone (LoE
IV). There have been no controlled trials of footwear in pa-
tients with hip OA and no controlled trials to support the hy-
pothesis52 that sports shoes or other footwear with shock
absorbing soles provide symptomatic beneﬁt in patients
with lower limb OA (hip or knee) by reducing impact loads.
10. Some thermal modalities may be effective for
relieving symptoms in hip and knee OA.
SOR: 64% (95% CI 60e68)
Heat and cryotherapy are used very widely in the man-
agement of patients with OA. Heat can be administered
by a variety of techniques including diathermy and the appli-
cation of heat packs or immersion in warm water or wax
baths, while cryotherapy is usually administered by applica-
tion of ice packs or massage with ice. Thermotherapy of
one kind or another is recommended in 7/10 existing guide-
lines where these modalities were considered4. Supporting
evidence is very limited. A single systematic review53 (LoE
Ia) analysed two RCTs of ice massage in 100 patients with
knee OA54 and ice packs or short wave diathermy in two
groups of 15 and 17 patients with knee OA55. Massaging
with ice for 20 min 5/week for 2 weeks resulted in clini-
cally signiﬁcant (29%) improvement in quadriceps strength
(ES¼ 1.03, 95% CI 0.44, 1.62) but had no clinically signiﬁ-
cant effect on the range of movement or on walking54. Ap-
plication of ice packs 3/week for 3 weeks was followed by
some improvement in pain (weighted mean difference,
WMD 2.70 95% CI 5.52, 0.12)55, but this was not statis-
tically signiﬁcant. Short wave diathermy was not followed by
any improvement in pain after 3 weeks and there was no
evidence of clinical beneﬁt following either modality of
thermotherapy after 3 months55. There have been no con-
trolled trials of thermotherapy for patients with hip OA.
11. Transcutaneous electrical nerve stimulation
(TENS) can help with short-term pain control in
some patients with hip or knee OA.
SOR: 58% (95% CI 45e72)
TENS is a recommended treatment for relief of pain in 8/
10 existing guidelines for the management of knee OA4.
Evidence for efﬁcacy available to the OARSI treatment
guidelines development group was summarised in a Co-
chrane systematic review published in 200056 and a system-
atic review published in 200457 (NNT¼ 2, 95% CI 1, 5) (LoE
Ia). The short-term efﬁcacy of 2e4 weeks treatment with
TENS in providing clinically signiﬁcant pain relief in patientswith knee OA has been subsequently conﬁrmed in a recent
systematic review and MA of seven RCTs involving 425 pa-
tients58. Dose-dependent inhibition of nociceptive nerve
transmission at a segmental level may provide a physiolog-
ical rationale59 for the efﬁcacy of TENS, and no serious
adverse effects of therapy have been reported58.
12. Acupuncture may be of symptomatic beneﬁt in
patients with knee OA.
SOR: 59% (95% CI 47e71)
Acupuncture is recommended as a modality of therapy
for the symptomatic treatment of patients with OA knee or
hip in 5/8 existing guidelines in which it was considered4,
and its recommendation achieved a 69% consensus follow-
ing the Delphi exercise. A summary of the evidence for its
clinical efﬁcacy in lower limb joint OA which was available
to the OARSI treatment guideline development group
showed moderate ESs for pain (ES¼ 0.51, 95% CI 0.23,
0.79), stiffness (ES¼ 0.41, 95% CI 0.13, 0.69) and function
(ES¼ 0.51, 95% CI 0.23, 0.79) with an NNT of 4 (95% CI 3,
9) for clinically signiﬁcant relief of pain60 (LoE Ib). An earlier
(2001) systematic review of the evidence for the efﬁcacy of
acupuncture in OA knee which included seven RCTs and
393 patients suggested that real acupuncture was more ef-
fective than sham acupuncture for relief of pain (LoE Ia) but
the evidence with regard to improvement in function was in-
conclusive61. A very recent RCT in 352 patients with knee
OA showed very small, statistically signiﬁcant, improve-
ments in pain intensity in patients 2 and 6 weeks following
true acupuncture but the addition of acupuncture to a course
of advice and exercises delivered by physiotherapists pro-
vided no additional improvement in the WOMAC index
pain subscale at 6 months62.
Pharmacological modalities of treatment
13. Acetaminophen (paracetamol) (up to 4 g/day) can
be an effective initial oral analgesic for treatment
of mild to moderate pain in patients with knee or
hip OA. In the absence of an adequate response,
or in the presence of severe pain and/or inﬂamma-
tion, alternative pharmacologic therapy should be
considered based on relative efﬁcacy and safety,
as well as concomitant medications and co-
morbidities.
SOR: 92% (95% CI 88e99)
Acetaminophen (paracetamol) is a core recommendation
for use as an analgesic in 16/16 existing guidelines for the
management of hip or knee OA4. Current European (EU-
LAR) recommendations for the management of hip63 and
knee64 OA suggest that, because of its safety and efﬁcacy,
doses of up to 4 g/day should be the oral analgesic of ﬁrst
choice for mild/moderate pain, and if successful, should
be used as the preferred long-term oral analgesic. How-
ever, in recent years both the efﬁcacy65 and the safety66,67
of long-term use of acetaminophen at this dose have been
questioned. Evidence for efﬁcacy available to the OARSI
treatment guideline development committee was summar-
ised in a Cochrane systematic review68 largely based on
a single RCT published before July 2002 and an MA of
10 RCTs published in 200469 with data from 1712 OA pa-
tients (LoE Ia). Efﬁcacy was conﬁrmed but the ES was small
(ES¼ 0.21, 95% CI 0.02, 0.4)69. A more recently updated
Cochrane systematic review published in 200670 included
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NSAIDs). Acetaminophen was superior to placebo in 5/7 tri-
als and pooled analysis of data on overall pain using multi-
ple methods showed a statistically signiﬁcant, but very
small, reduction in pain (ES¼ 0.13, 95% CI 0.04, 0.22)
which is of questionable clinical signiﬁcance. The NNT to
achieve an improvement in pain ranged from 2 (1, 2)68 in
the earlier systematic review to 4e1670 in the later MA.
There was no signiﬁcant difference in toxicity between acet-
aminophen and placebo in these short-term trials (RR¼
1.02, 95% CI 0.89, 1.87)70. The evidence for possible gastro-
intestinal (GI) and renal toxicity with long-term treatment with
acetaminophen 4 g/day, reviewed in the ﬁrst part of this re-
port4, remains equivocal. The RR for upper GI bleeding or
perforation ranged from RR 1.2 (95% CI 0.8, 1.7)71 in a MA
of three caseecontrol studies with individual patient data to
RR 3.6 (95% CI 2.60, 5.10)66 in a caseecontrol study using
the UK General Practice Research Database; and the RR
of renal insufﬁciency ranged from RR 0.83 (95% CI 0.50,
1.39) in one cohort study (CS)72 to RR 2.5 (95% CI 1.7,
2.6) in a caseecontrol comparison73.
14. In patients with symptomatic hip or knee OA,
non-steroidal anti-inﬂammatory drugs (NSAIDs)
should be used at the lowest effective dose but
their long-term use should be avoided if possible.
In patients with increased GI risk, either a COX-2
selective agent or a non-selective NSAID with co-
prescription of a proton pump inhibitor (PPI) or
misoprostol for gastroprotection may be consid-
ered, but NSAIDs, including both non-selective
and COX-2 selective agents, should be used
with caution in patients with cardiovascular (CV)
risk factors.
SOR: 93% (95% CI 88e99)
The use of oral NSAIDs with misoprostol or a PPI for gas-
troprotection is recommended in 8/8 existing guidelines for
the management of hip or knee OA4 and the use of selec-
tive COX-2 inhibitors is recommended in all 11 of the guide-
lines where this modality of therapy was considered4. A
telephone survey of 1149 patients with OA in the UK in
2003 revealed that only 15% were taking paracetamol,
while 32% were taking non-selective NSAIDs and 18%
COX-2 selective drugs for analgesia74. There is evidence
that NSAIDs can be effective in reducing pain in patients
with OA knee and hip (LoE Ia). A 2004 MA of 23 short-
term, placebo-controlled RCTs of NSAIDs, including COX-
2 selective agents in >10000 patients with knee OA,
showed that the ES for pain reduction was 0.32 (95% CI
0.24, 0.39)75. However in 10 trials that did not exclude
non-responders where the outcomes were more homoge-
neous the ES for pain reduction was smaller (ES¼ 0.23,
95% CI 0.15, 0.31)75. Evidence that NSAIDs are superior
to acetaminophen for pain relief in patients with lower limb
joint OA is available from another 2004 MA of RCTs69
(ES¼ 0.20, 95% CI 0.10, 0.30). The clinical response rate
was higher (RR¼ 1.24, 95% CI 1.08, 1.41) and the number
of patients preferring NSAIDs to acetaminophen was con-
siderably greater (RR¼ 2.46, 95% CI 1.51, 4.12)69. The
ESs for pain relief in short-term trials are, however, less
than 0.4, which has been suggested as the minimum to
be of any clinical importance76.
There is abundant evidence that NSAIDs are associated
with more adverse effects than acetaminophen in short-
term trials. The 2004 MA69 showed that NSAIDs were
associated with GI discomfort more frequently thanacetaminophen (RR¼ 1.35, 95% CI 1.05, 1.75) and this
was conﬁrmed in the more recent Cochrane systematic re-
view of short-term RCTs (RR¼ 1.47, 95% CI 1.08, 2.00)70.
More importantly NSAIDs can cause serious GI complica-
tions such as peptic ulcers, perforations and bleeds
(PUBS) and this risk increases with age, concurrent use
of other medications, and probably with the duration of ther-
apy77. A MA of severe upper GI complications of NSAIDs
showed an OR of 5.36 (95% CI 1.79, 16.1) in 16 NSAID
vs placebo trials in 4431 patients and a pooled OR for
PUBS of 3.0 (95% CI 2.5, 3.7) in 23 caseecontrol studies
in 25,732 patients78. The pooled RR of PUBS from nine co-
hort studies representing >750,000 person years of drug
exposure was 2.7 (95% CI 2.1, 3.5)78. The recommendation
that in patients with increased GI risk, either a COX-2 selec-
tive agent or a non-selective NSAID with co-prescription of
a PPI or misoprostol for gastroprotection should be consid-
ered is supported by evidence from a systematic review of
112 RCTs which included nearly 75,000 patients79 (LoE Ia).
The RRs for symptomatic ulcers and serious GI complica-
tions with these different strategies are shown in Table III.
There was no evidence for similar gastroprotection with
H2 receptor antagonists and treatment with misoprostol is
associated with an increased risk of diarrhoea (RR¼ 1.81,
95% CI 1.52, 2.61)80 and the GI protection that is associ-
ated with the use of COX-2 selective agents is largely lost
when low-dose aspirin is administered concurrently for CV
prophylaxis81.
What is the evidence to support the recommendation that
NSAIDs, including both non-selective and COX-2 selective
agents, should be used with caution in patients with CV risk
factors? Following the withdrawal of the COX-2 selective
NSAID rofecoxib in 2004 because of an increased RR of
thrombotic CV events including myocardial infarction and
stroke in a colorectal adenoma chemoprevention trial82
a number of RCTs and systematic reviews of the CV safety
of other COX-2 selective and non-selective NSAIDs have
been undertaken83e86. Table IV shows the RRs for CV
events in patients treated with COX-2 selective and non-
selective NSAIDs. While the increased risk of CV adverse
events with rofecoxib was conﬁrmed, similar CV toxicity
was not seen consistently with celecoxib or valdecoxib
and the overall CV risk associated with COX-2 selective in-
hibitors was not signiﬁcantly greater than that associated
with conventional non-selective NSAIDs (RR¼ 1.19, 95%
CI 0.80, 1.75)79. This has been borne out in the more recent
2006 systematic review and MA of atherothrombotic compli-
cations of COX-2 selective and non-selective NSAIDs87.
The incidence of serious vascular events was 1% per
annum in patients treated with COX-2 selective agents
compared with 0.9% in those on traditional NSAIDs
(RR¼ 1.16, 95% CI 0.97, 1.38)87. There was, however,
some heterogeneity in risk among the traditional NSAIDs
with a modest increase in risk of CV events with ibuprofen
(RR¼1.51, 95% CI 0.96, 2.37) and diclofenac (RR¼ 1.63,
95% CI 1.12, 2.37) but not with naproxen (RR¼ 0.92,
95% CI 0.67, 1.26)87. The current advice88 from the Euro-
pean Agency for the Evaluation of Medicinal Products
(EMEA) is that COX-2 selective NSAIDs are contraindi-
cated in patients with ischaemic heart disease or stroke
and that prescribers should exercise caution when prescrib-
ing COX-2 inhibitors for patients with risk factors for heart
disease, such as hypertension, hyperlipidaemia, diabetes
and smoking, as well as for patients with peripheral arterial
disease. In the USA all marketed prescription NSAIDs, both
non-selective and COX-2 selective carry a boxed warning
about their potential for causing CV events and GI bleeding.
Table III
Relative risk of GI adverse events associated with NSAIDs and strategies for their prevention
Intervention* Adverse events RR/OR (95% CI) Evidence
Acetaminophen GI discomfort 0.80 (0.27, 2.37) MA of RCTs69
GI perforation/bleed 3.60 (2.60, 5.10) CC66
GI bleeding 1.2 (0.8, 1.7) MA of CCs71
NSAIDs GI perforation/ulcer/bleed 5.36 (1.79, 16.10) MA of RCTs78
2.70 (2.10, 3.50) MA of CSs78
3.00 (2.70, 3.70) MA of CCs78
Topical NSAIDs GI events 0.81 (0.43, 1.56) MA of RCTs89
GI bleed/perforation 1.45 (0.84, 2.50) CC92
H2 blockerþNSAID vs NSAID Serious GI complications 0.33 (0.01, 8.14) MA of RCTs79
Symptomatic ulcers 1.46 (0.06, 35.53)
PPIþNSAID vs NSAID Serious GI complications 0.46 (0.07, 2.92) MA of RCTs79
Symptomatic ulcer 0.09 (0.02, 0.47)
MisoprostolþNSAID vs NSAID Serous GI complications 0.57 (0.36, 0.91) MA of RCTs79
Symptomatic ulcers 0.36 (0.20, 0.67)
Diarrhoea 1.81 (1.52, 2.61) MA of RCTs80
COX-2 inhibitors vs NSAID Serious GI complications 0.55 (0.38, 0.80) MA of RCTs79
Symptomatic ulcers 0.49 (0.38, 0.62)
RR: relative risk; OR: odds ratio; CI: conﬁdence interval; GI: gastrointestinal; NSAID: non-steroidal anti-inﬂammatory drug; H2 blockers:
histamine type 2 receptor antagonists.
*Compared with placebo/non-exposure unless otherwise stated.
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 Prescribers and patients should continue to use
NSAIDs at the lowest effective dose for the shortest du-
ration to control symptoms.
 Prescribers should continue to chose any NSAID on the
basis of the overall safety proﬁle of the product, as set
out in the product information, and the patient’s individ-
ual risk factors.
 Prescribers should not switch between NSAIDs without
careful consideration of the overall safety proﬁle of the
products and the patient’s individual risk factors, as well
as the patient’s preferences.
15. Topical NSAIDs and capsaicin can be effective as
adjunctives and alternatives to oral analgesic/
anti-inﬂammatory agents in knee OA.
SOR: 85% (95% CI 75e95)Table I
Relative risks of CV and renal adverse events associate
Intervention* Adverse events
Acetaminophen Renal failure
NSAIDs Myocardial infarction
H2 blockerþNSAID vs NSAID Serious CV or renal events
PPIþNSAID vs NSAID Serious CV or renal events
MisoprostolþNSAID vs NSAID Serious CV or renal events
COX-2 inhibitors
Coxibs vs NSAID Serious CV or renal events
Celecoxib Myocardial infarction
Rofecoxib Myocardial infarction
Valdecoxib CV events
CV: cardiovascular; please see the footnotes of Table III for other abb
*Compared with placebo/non-exposure unless otherwise stated.Topical NSAIDs are widely used as adjunctive or alterna-
tive therapy by patients with OA knee and are recommen-
ded in 7/9 existing guidelines where this modality of
therapy was considered4. A MA of 13 RCTs, including
1983 patients with hand as well as knee OA, undertaken
in 2004 conﬁrmed that topical NSAIDs were superior to pla-
cebo in relieving pain and stiffness and in improving func-
tion (LoE Ia)89. Efﬁcacy for pain relief was only apparent
in the ﬁrst 2 weeks of treatment with ESs of 0.41 (95% CI
0.16, 0.66) in week 1 and 0.40 (95% CI 0.15, 0.65) in
week 2 but topical NSAIDs are less effective than oral
NSAIDs in the ﬁrst week of treatment. The NNT for topical
NSAIDs was only 3 (95% CI 2, 4) but placebo effects may
be large with all topical therapies. The ESs for improvement
in stiffness and in function were 0.49 (95% CI 0.17, 0.80)
and 0.36 (95% CI 0.24, 0.48), respectively. However the
MA showed evidence of statistically signiﬁcant asymmetry
of a funnel plot90 suggesting the possibility of publicationV
d with COX-2 selective and non-selective NSAIDs
RR/OR (95% CI) Evidence
0.83 (0.50, 1.39) CS72
2.5 (1.7, 3.6) CC73
1.09 (1.02, 1.15) MA of CSs83
0.53 (0.08, 3.46) MA of RCTs79
0.78 (0.10, 6.26) MA of RCTs79
1.78 (0.26, 12.07) MA of RCTs79
1.19 (0.80, 1.75) MA of RCTs79
2.26 (1.0, 5.1) MA of RCTs84
0.97 (0.86, 1.08) MA of CSs & CCs83
2.24 (1.24, 4.02) MA of RCTs85
1.27 (1.12, 1.44) MA of CSs and CCs83
2.3 (1.1, 4.7) MA of RCTs86
reviations.
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quent overestimation of the beneﬁts of topical NSAIDs.
This MA provided no trial evidence to support long-term
use of topical NSAIDs in knee OA but there was some het-
erogeneity of efﬁcacy between preparations and a more
recent MA did demonstrate a small pooled effect
(ESpain¼ 0.28, 95% CI 0.14, 0.42)91. Overall topical
NSAIDs are safe with no more side effects than placebo89.
GI side effects are less likely than they are with oral
NSAIDs89,90 and there was no evidence that they could
be a cause of upper GI perforation or bleeds in a large
caseecontrol study92 (Table III). However local reactions
such as itching, burning and rashes are more frequent89.
Topical capsaicin creams contain a lipophilic alkaloid ex-
tracted from chilli peppers which activates and sensitises pe-
ripheral c-nociceptors by binding and activating the transient
receptor potential vanilloid type 1 (TRPV1) cation channel93.
Paradoxically, although the application of capsaicin to the
skin causes burning pain at the site of application, it can
also be an effective topical analgesic which is recommended
as an alternative or adjunctive treatment for knee OA in 8/9
existing treatment guidelines where this modality of therapy
was considered4. Evidence for the efﬁcacy of topical capsa-
icin (0.025%cream 4 daily) in patients with kneeOA is sup-
ported by anMA of RCTs of topical capsaicin in the treatment
of chronic painful conditions94 (LoE Ia). This included a single
placebo-controlled trial in 70 patients with knee OA95 as well
as twoRCTs in patients with handOA. Themean reduction in
pain was 33%with an NNT of 4 (95%CI 3, 5) after 4 weeks of
therapy but adequate blinding is not possible in trials with this
agent. Treatment with topical capsaicin is safe but 40%of pa-
tients are troubled by local burning, stinging or erythema.
16. Intra-articular (IA) injections with corticosteroids
can be used in the treatment of hip or knee OA,
and should be considered particularly when pa-
tients havemoderate toseverepainnot responding
satisfactorily to oral analgesic/anti-inﬂammatory
agents and in patients with symptomatic knee OA
with effusions or other physical signs of local
inﬂammation.
SOR: 78% (95% CI 61e95)
IA injections of corticosteroids have been widely used as
adjunctive therapy in the treatment of patients with knee OA
for more than 50 years96, and are recommended as a treat-
ment option in 11/13 of existing treatment guidelines where
this modality of therapy was considered4. The efﬁcacy of IA
steroid injections in patients with knee OA is well supported
by evidence from a 2005 Cochrane systematic review97
(LoE Ia), subsequently updated in 200698, which examined
data from 13 placebo-controlled RCTs. The ES for relief of
pain was in the moderate range (ES¼ 0.72, CI 0.42, 1.02)
with an NNT of 4 (95% CI 2, 11) at 2 and 3 weeks after in-
jection but function was not signiﬁcantly improved
(ES¼ 0.06, 95% CI 0.17, 0.30) and evidence for relief of
pain 4 and 24 weeks post-injection was lacking97. Some
RCTs have demonstrated better outcomes in patients with
synovial effusions99 but others have not found that clinical
signs of inﬂammation or the presence of a joint effu-
sion100,101 are predictors of a good clinical response; sug-
gesting that IA steroid injections should not be restricted
to patients with physical signs of inﬂammation and/or joint
effusion. A single RCT102 in 42 patients with knee OA with
signs of inﬂammation showed that IA injections of 20 mg
of triamcinolone hexacetonide were superior to 6 mg of a be-
tamethasone acetate/bisodium phosphate combination forthe number of patients reporting pain reduction up to 4
weeks after injection (RR¼ 2, 95% CI 1.10, 3.63) but the
number of head to head comparisons between different IA
corticosteroid preparations is too few to support any evi-
dence-based recommendations for a particular preparation.
By contrast the evidence to support the recommendation
for IA steroid injection in patients with OA hip is mainly lim-
ited to two RCTs103,104 (LoE Ib) and two uncontrolled cohort
studies105,106. In one RCT an IA injection combining bupiva-
caine and triamcinolone did not give better pain relief than
IA injections of saline after 1 month (RR¼ 1.18, 95% CI
0.68, 2.15) or after 3 months (RR¼ 0.61, CI 0.23, 1.60);
and the combination containing IA steroid was not better
than injections of local anaesthetic alone in patients with
OA awaiting hip joint replacement103. A second RCT in 80
patients with severe symptomatic OA hip compared the ef-
fects of ﬂuoroscopically controlled IA injection of 80 mg
triamcinolone hexacetonide or 1% mepivacaine and demon-
strated signiﬁcant reduction in pain and improved mobility
after 3 weeks and 3 months in the steroid treated patients
but not in those treated with IA injections of local
anaesthetic104.
No serious adverse events were reported as a conse-
quence of IA steroid injections in 1973 patients in 28 con-
trolled trials in patients with OA knee98. Potential side
effects include post-injection ﬂares of pain, crystal synovitis,
haemarthrosis, joint sepsis and steroid articular cartilage at-
rophy, as well as systemic corticosteroid effects such as
ﬂuid retention or aggravation of hypertension or diabetes
mellitus. Emphasis has been placed on the importance of
accurate placement of IA injections to maximise beneﬁt
and reduce the risk of adverse effects such as fat necrosis
and para-articular tissue atrophy107. There are limited data
at present to indicate how frequently it is safe to administer
IA steroid injections to patients with OA hip or knee. Most
experts recommend caution regarding too-frequent use; re-
peat injections more than four times annually are generally
not recommended.
17. Injections of IA hyaluronate may be useful in
patients with knee or hip OA. They are character-
ised by delayed onset, but prolonged duration, of
symptomatic beneﬁt when compared to IA injec-
tions of corticosteroids.
SOR: 64% (95% CI 43e85)
Hyaluronic acid is a large molecular weight glycosamino-
glycan which is a constituent of synovial ﬂuid in normal and
osteoarthritic joints. IA injection of hyaluronan (HA), with rel-
atively high and low molecular weight averages, is widely
used, and recommended in 8/9 existing guidelines as a use-
ful therapeutic modality for treating patients with OA knee
as a viscosupplement or pharmaceutical4, despite consider-
able ongoing controversy with regard to its efﬁcacy, cost-
effectiveness and beneﬁt to risk ratio. The evidence
available to the OARSI treatment guidelines development
group from the critical appraisal of existing guidelines and
the systematic review of the research evidence from 2002
to January 2006 was derived from two systematic reviews
published in 2003108 and 2005109 (LoE Ia). The pooled
ES for reduction in pain at 2e3 months following at least
three IA injections at weekly intervals in 22 placebo-con-
trolled RCTs was 0.32 (95% CI 0.17, 0.47). There was,
however, signiﬁcant heterogeneity between studies with in-
conclusive data to suggest that the higher molecular weight
HA preparations may be more effective108. An asymmetric
funnel plot and a positive Egger test also suggested the
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published trials with a pooled ES of 0.07 (95% CI 0.15,
0.28) further suggested that the overall ES might have been
overestimated108. The 2005 MA found no evidence of im-
provement in function in pooled results from nine placebo-
controlled RCTs which included joint function as an out-
come (ES¼ 0.00, 95% CI 0.23, 0.23) and no effects on
pain during movement compared with saline injections
that were judged to be clinically meaningful at any time
point after treatment109. Two further systematic reviews of
IA injections of HA in patients with OA knee were published
in 2006110,111. One MA of seven placebo-controlled RCTs
which used the WOMAC or Lequesne indexes as outcome
measurements found small but signiﬁcant improvements in
the Lequesne index, but not in the WOMAC scales for self-
reported pain or disability up to 6 months after treatment110.
A more comprehensive industry-sponsored Cochrane re-
view which included an MA of 40 placebo-controlled trials
with ﬁve different commercially available HA products found
statistically signiﬁcant improvements in pain on weight bear-
ing when results were pooled (WMDs of 8, 13, 9 and
3 at 1e4, 5e13, 14e26 and 45e52 weeks, respectively),
but improvements from baseline to the maximum at 5e13
weeks varied from 28% to 54% for pain and from 9% to
32% for function with different products111. In 10 trials com-
paring IA HA injections with IA corticosteroids there were no
signiﬁcant differences 4 weeks after injection but IA HA was
shown to be more effective 5e13 weeks post-injection for
one or more of a number of outcome variables (WOMAC
OA index, Lequesne index, pain, range of ﬂexion, and num-
ber of responders)98,111. No major safety issues were de-
tected111 but in placebo-controlled trials minor adverse
events such as transient pain at the injection site occurred
slightly more frequently in patients treated with IA HA
(RR¼ 1.08, 95% CI 1.01, 1.15)109. A recent study112 used
the decision algorithm proposed by Jadad et al.113 and
the GRADE (Grades of Recommendation Assessment,
Development and Evaluation)114 system to explore the rea-
sons for discordant conclusions in six published systematic
reviews of IA HA for the treatment of OA knee108e111,115,116.
The reasons for inconsistency identiﬁed included inclusion
of different controlled trials as a result of different search
strategies and selection criteria, differences in the outcome
measures and time points selected for extraction; and differ-
ent statistical methods for data synthesis, which resulted in
conﬂicting estimates of therapeutic effect112. There is much
less research evidence to support the proposition that IA in-
jections of HA can be a useful treatment in patients with hip
OA. Three quasi systematic reviews have examined the re-
sults of a number uncontrolled clinical trials and case seri-
es117e119, a single comparison of injection of a low or
high molecular weight HA120, and a single, double blind,
three armed RCT in 101 patients with hip OA in which IA in-
jections of a low molecular weight HA preparation were
compared with IA saline and IA corticosteroid injections121.
In the randomised comparison of three injections of high
and low molecular weight HA given at weekly intervals
under ﬂuoroscopic control there were signiﬁcant improve-
ments of approximately 40% in VAS, WOMAC and Le-
quesne index scores 1, 3 and 6 months after treatment
but no signiﬁcant differences at any of the time points be-
tween the two groups120. However in the placebo-controlled
trial in which three injections of HA, corticosteroid or saline
were given with ultrasound guidance at 2 weekly intervals,
there were no signiﬁcant differences between the HA treated,
corticosteroid treated or saline treated groups in pain on walk-
ing, WOMAC or Lequesne indices 14, 28 or 90 days after thecourse of injections121. Responses at 14 days applying
OARSI response criteria were 53% in patients treated with
HA, 56% in the corticosteroid treated group and 33% in the
placebo-treated patients. At 28 days 53% responded to HA,
66% to corticosteroids and 44% to placebo121.
18. Treatment with glucosamine and/or chondroitin
sulphate may provide symptomatic beneﬁt in
patients with knee OA. If no response is apparent
within6months treatment shouldbediscontinued.
SOR: 63% (95% CI 44e82)
The aminosugar glucosamine and the glycosaminogly-
can chondroitin sulphate are both naturally occurring con-
stituents of cartilage proteoglycans that are very widely
used as ‘nutritional supplements’ by patients with OA122.
A crystalline preparation of glucosamine sulphate is ap-
proved as a medicinal product for the treatment of OA in
many countries in Europe, Asia and Latin America. Glucos-
amine sulphate is recommended in 6/10 existing guidelines
for the management of hip or knee OA, but chondroitin sul-
phate in only 2/7 guidelines where these modalities of ther-
apy were considered4, and there is continuing controversy
as to the efﬁcacy of these agents as symptom modifying
drugs.
Evidence available to the guideline development commit-
tee concerning the efﬁcacy and safety of glucosamine was
mainly derived from the 2005 update of the Cochrane sys-
tematic review and MA123 and an earlier MA published in
2003124 (LoE Ia). In comparisons with placebo, pooled anal-
ysis of 20 RCTs involving 2570 patients with knee OA
showed a 28% improvement in pain (ES¼ 0.61, 95% CI
0.28, 0.95) and a 21% improvement in function using the
Lequesne index (ES¼ 0.51, 95% CI 0.96, 0.05)123. How-
ever WOMAC pain, stiffness and function were not signiﬁ-
cantly changed and there was considerable heterogeneity
of outcomes in different trials. With such marked heteroge-
neity, pooling of results may not be appropriate and esti-
mates of overall ESs may be misleading. The possible
reason(s) for the variation in outcomes also requires an
explanation. In 10 placebo-controlled RCTs in which the
Rottapharm preparation of glucosamine sulphate 1500 mg
daily was used there were signiﬁcant improvements in
pain (ES¼ 1.31, 95% CI 0.64, 1.99) and function (ES¼
0.51, 95% CI 0.05, 0.96) while there were no signiﬁcant im-
provements in WOMAC pain or function indices in the
pooled results of RCTs that used other glucosamine formu-
lations123. Analysis of the eight RCTs in which allocation
concealment was considered adequate also failed to
show drug efﬁcacy for relief of pain or improvement in func-
tion using the WOMAC index123. A more recent systematic
review was undertaken speciﬁcally to try and identify the
factors that might be responsible for the heterogeneity of
outcomes in trials of glucosamine125. In 15 RCTs which
met the inclusion criteria the summary of ES for pain relief
was 0.35 (95% CI 0.14, 0.56) but there was a considerable
variation in outcomes attributable to differences between
studies, rather than to chance126, with an I 2 of 80%125
(i.e., 80% of the inconsistency could be attributed to the
true differences between studies). An Egger test and funnel
plot90 did not suggest publication bias and there were no
clear indications that the heterogeneity was attributable to
differences in trial design, trial quality, the number of drop-
outs or differences in intention to treat analyses, but the dif-
ferences in adequacy of the allocation concealment
detected in the Cochrane review123 were conﬁrmed. The
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the glucosamine preparation that was used. The ES for tri-
als which used glucosamine sulphate was 0.44 (95% CI
0.18, 0.70) compared with 0.06 (95% CI 0.08, 0.20) for
those that used glucosamine hydrochloride, and the ES
for trials utilising the Rottapharm preparation of glucos-
amine sulphate was 0.55 (95% CI 0.29, 0.82) compared
with an ES of 0.11 (95% CI 0.16, 0.38) for trials with other
products. The possibility of industry bias as an additional or
alternative explanation for the heterogeneity of outcomes
between glucosamine trials was also suggested, but not
substantiated125. In the ﬁrst part of this report it was shown
that sensitivity analysis following addition of the data from
two large multicentre RCTs which were published after the
closeof the systematic review in January 2006; theNIHspon-
sored Glucosamine/chondroitin Arthritis Intervention Trial
(GAIT)127 in which glucosamine hydrochloride was used,
and the Glucosamine Unum in Die Efﬁcacy (GUIDE) trial128
inwhich glucosamine sulphate 1500 mgdailywas employed,
to the main body of trial outcomes, did not alter the ESs for
pain efﬁcacy signiﬁcantly4. The NNT for treatment of knee
OAwith glucosamine sulphate is 5 (95%CI 4, 7)124 and treat-
ment is not associated with any serious adverse effects123.
The evidence supporting the recommendation that chon-
droitin sulphate may provide symptomatic beneﬁt in patients
with knee OA is also conﬂicting. At the time of the Delphi ex-
ercise the evidence for efﬁcacy of chondroitin sulphate was
supported by two MAs published in 2000129,130 and a third
one in 2003124 (LoE Ia). Analysis of eight RCTs involving
755 patients showed a moderate ES for pain reduction
(ES¼ 0.52, 95% CI 0.37, 0.67) with an NNT of 5 (4, 7)
and no evidence of serious side effects124. However, as
shown in the ﬁrst part of this report4, sensitivity analysis fol-
lowing addition of the data from the GAIT study127 to the
main body of trial outcomes reduced the ES for pain reduc-
tion signiﬁcantly (ES¼ 0.30, 95% CI 0.10, 0.70) and sug-
gested that treatment with chondroitin sulphate was not
signiﬁcantly more effective than placebo. This was also
the conclusion of the most recent systematic review and
MA131. In their analysis of 20 trials involving 3846 patients
the ES for pain relief was large (ES¼ 0.75, 95% CI 0.50,
0.99) but they identiﬁed very marked heterogeneity of out-
comes between trials with an I 2 of 92%. Small trials with
poor quality features such as uncertain concealment of allo-
cation and a failure to analyse results on an intention to
treat basis showed larger effects in favour of chondroitin
than did the remaining trials131. Similar caveats had been
raised in one of the earlier MAs130. When Reichenbach
et al. restricted the analysis to three recent trials with large
sample sizes and an intention to treat analysis127,132,133;
the ES for pain reduction was only 0.03 (95% CI 0.07,
0.13) with an I2 of 0%131. However this restricted analysis
included one study with an exceptionally high placebo re-
sponse rate127, one study that was only published as an ab-
stract132 and only 40% of all trial patients. The pooled RR
for adverse events in an MA of 12 placebo-controlled trials
was 0.99 (95% CI 0.76, 1.21)131.
19. In patients with symptomatic knee OA glucos-
amine sulphate and chondroitin sulphate may
have structure-modifying effects while diacerein
may have structure-modifying effects in patients
with symptomatic OA of the hip.
SOR: 41% (95% CI 20e62)
Evidence that glucosamine sulphate 1500 mg/day may
have structure-modifying effects in patients with knee OAcomes from two placebo-controlled RCTs involving 414 pa-
tients134,135 and two systematic reviews and MAs123,124
(LoE Ia). In one trial there was no radiographic loss of joint
space width (JSW) in the medial compartment of the tibio-
femoral joint after 3 years (mean 0.06 mm, 95% CI
0.22, 0.09) in the treated patients compared with progres-
sive loss in the placebo group (mean 0.31 mm, 95% CI
0.48, 0.13)134. The pooled results of both trials showed
an ES¼ 0.24 (95% CI 0.04, 0.43)123.
The proposition that chondroitin sulphate (800 mg/day)
may also have structure-modifying effects is supported by
an MA of ﬁve placebo-controlled RCTs. The difference in
changes over 2 years between chondroitin and placebo
demonstrated a small effect in favour of chondroitin:
0.16 mm on minimum JSW (95% CI 0.08, 0.24) and
0.23 mm on mean JSW (95% CI 0.09, 0.37)131 (LoE Ia).
The evidence to support the proposition that diacerein
may have structure-modifying effects in patients with hip
OA comes from a single 3-year placebo-controlled RCT in
507 patients with primary hip OA136 and a systematic re-
view and MA137 (LoE Ia). In patients who completed 3 years
of therapy with diacerein 50 mg twice daily the rate of joint
space narrowing was [mean standard deviation (SD)]
0.18 0.25 mm/year vs 0.23 0.23 mm/year with placebo
(P¼ 0.042)136. Similar structure-modifying effects were
not evident in a 1-year placebo-controlled RCT in patients
with knee OA138.
20. The use of weak opioids and narcotic analgesics
can be considered for the treatment of refractory
pain in patients with hip or knee OA, where other
pharmacological agents have been ineffective, or
are contraindicated. Stronger opioids should
only be used for the management of severe pain
in exceptional circumstances. Non-pharmacolog-
ical therapies should be continued in such
patients and surgical treatments should be
considered.
SOR: 82% (95% CI 74e90)
The use of opioid analgesics is recommended in 9/9 ex-
isting treatment guidelines for the management of hip or
knee OA4. A number of systematic reviews and MAs of
the use of opioids for chronic non-cancer pain139,140, mus-
culoskeletal pain141 and more recently OA142 have provided
evidence of efﬁcacy and acceptable safety in short-term tri-
als (LoE Ia). Analysis of 18 placebo-controlled RCTs includ-
ing 3244 patients with OA showed a moderate ES for
reduction in pain intensity (ES¼ 0.78, 95% CI 0.59, 0.98)
but there was substantial heterogeneity between studies
which was not obviously related to the opioid preparation
that was used or the methodological quality of the
RCTs142. The median duration of trials was 12 weeks
(range 1.4e72 weeks)142. Analysis of ﬁve placebo-con-
trolled RCTs which included 1429 OA patients receiving
opioids showed a small effect on improvement in physical
function (ES¼ 0.31, 95% CI 0.24, 0.39)142. Beneﬁts asso-
ciated with the use of opioids were, however, limited by fre-
quent side effects; nausea (30%), constipation (23%),
dizziness (20%), somnolence (18%) and vomiting (13%)142.
Overall 25% of patients treated with opioids withdrew from
studies compared with 7% of placebo-treated patients
with a number needed to harm (NNH) of 5. The withdrawal
rate for strong opioids (oxymorphone, oxycodone, oxytrex,
fentanyl, morphine sulphate) was 31% (NNH 4) compared
with a withdrawal rate of 19% and an NNH of 9 for the
weaker opioids (tramadol, tramadol/paracetamol, codeine
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clusions concerning comparisons of the efﬁcacy or safety
of opioids and other available analgesics such as paraceta-
mol or NSAIDs because of the very limited number of head
to head trials. However, another MA of opioids for chronic
non-cancer pain, including OA, demonstrated that only
strong opioids were signiﬁcantly more effective than para-
cetamol or NSAIDs (ES¼ 0.34, 95% CI 0.01, 0.67)140. A
systematic review conducted a decade earlier had, how-
ever, conﬁrmed that paracetamolecodeine combinations
did provide a small (approximately 5%) but statistically sig-
niﬁcant analgesic beneﬁt when compared with paracetamol
alone, but adverse effects were more frequent (RR¼ 2.5,
95% CI 1.5, 4.2)143. All the systematic reviews highlight
the fact that there have been no long-term trials of the
use of opiates for treating patients with OA139e142. This is
obviously relevant because of ongoing concerns about the
risks of dependence or addiction to opiates144. While in
the USA there is evidence that the use of opioids for the
management of chronic musculoskeletal pain doubled
(RR¼ 2.0, 95% CI 1.52, 2.48) and the use of potent opioids
more than quadrupled (RR¼ 4.5, 95% CI 2.18, 6.87) be-
tween 1980 and 2000145, a survey of primary care physi-
cians in the UK published in 2006 suggested that as
many as 25% never prescribed opioids for patients with
persistent non-cancer related pain146 and this was mainly
determined by personal beliefs about the appropriateness
of prescribing opioids in these circumstances, rather than
evidence-based guidelines146.
21. Patients with hip or kneeOAwho are not obtaining
adequate pain relief and functional improvement
from a combination of non-pharmacological and
pharmacological treatment should be considered
for joint replacement surgery. Replacement ar-
throplasties are effective, and cost-effective inter-
ventions for patients with signiﬁcant symptoms,
and/or functional limitations associated with
a reduced health-related quality of life, despite
conservative therapy.
SOR: 96% (95% CI 94e98)
Total hip arthroplasty (THA) and knee joint arthroplasty
(TKA) are universally recommended in 14/14 existing treat-
ment guidelines4, and generally accepted as reliable and
appropriate surgical procedures to restore function and im-
prove health-related quality of life in patients with hip and
knee OA who are not obtaining adequate pain relief and
functional improvement with a combination of pharmaco-
logical and non-pharmacological treatments147,148. As eth-
ical and methodological considerations have precluded
evaluation of total joint replacement with RCTs, evidence
to support their efﬁcacy is based substantially on numerous
uncontrolled observational studies and a very small num-
ber of cohort studies where outcomes have been com-
pared with standard medical care (LoE III). These are
well summarised in a 2004 qualitative and systematic re-
view of the scientiﬁc literature relating to health-related
quality of life outcomes following THA and TKA149. This an-
alysed the outcomes in 74 arthroplasty studies (32 hip and
knee, 26 THA and 16 TKA alone) involving many thou-
sands of patients with OA. The Short Form-36 (SF-36) (40
studies) and the WOMAC index (28 studies) were the instru-
ments most frequently employed. Most studies reported on
post-operative outcomes up to 6 or 12 months but there
were some data on clinical outcomes up to 7 years following
surgery. All studies reported substantial improvements inpain and physical functioning but the effects on mental health
and social functioning were more variable149. Pain scores
improved more quickly and more dramatically than physical
functional outcomes with maximal improvements in the ﬁrst
3e6 months149. An earlier systematic review of outcomes fol-
lowing THR with different types of prosthesis in 118 uncon-
trolled studies involving 77,375 patients with a mean follow
up of 9.4 years (range 2e20 years) found that 43% (95%
CI 34, 49) to 84 (95% CI 46, 100) were free from pain, de-
pending on the type of prosthesis used. Revision rates
ranged from 0.18 (S.E.M. 0.04) to 2.04 (S.E.M. 0.19)/100 per-
son years150. MA of functional outcomes following unicom-
partmental151, bicompartmental151 and tricompartmental152
knee arthroplasty showed mean improvements in a global
knee score, incorporating pain, function and range of motion,
of 63%, 93%, and 100%, respectively, 4e6 years after sur-
gery. Cumulative revision rates at 10 years following THA
and TKA for OA hip and knee were 7%153 and 10%154,
respectively.
A number of studies have shown that quality of life indi-
ces following THA approximate to those in the age and gen-
der matched population155e157 a year after surgery. Overall
THA is more effective than TKA in restoring patients with
hip or knee OA to normal function and age is not an obsta-
cle to effective surgery149. However higher age, more pre-
operative pain, musculoskeletal co-morbidities such as
low back pain, and OA in the non-operated hip, predict
a poorer outcome following THA158. More severe pain,
functional limitation, low mental health scores and medical
co-morbidities have also been shown to predict a poorer
outcome following TKA159. Following development and
evaluation of explicit criteria for the appropriateness of indi-
cations for THA160 and TKA161, based on a method that
combines expert opinion with available scientiﬁc evi-
dence162, it has recently been demonstrated that physical
and social functions as assessed by the SF-36 and WO-
MAC instruments improved to a signiﬁcantly greater extent
following THA and TKA in patients where the indications for
surgery were appropriate163. THA and TKA were shown to
be more cost-effective treatments for the management of
hip and knee OA than current pharmacological modalities
of therapy in the ﬁrst part of this report4. The most recently
published data suggest that the cost per QUALY gained
from TKA (13995 Euros) is twice that gained from THA
(6710 Euros)164.
22. Unicompartmental knee replacement is effective
in patients with knee OA restricted to a single
compartment.
SOR: 76% (95% CI 64e88)
Approximately one third of patients with knee OA have
unicompartmental disease that is largely restricted to a sin-
gle compartment165. In approximately 30% of these patients
with unicompartmental knee OA the medial compartment is
affected, in 3% it is the lateral compartment and in 69% the
disease predominantly involves the patello-femoral joint165.
Evidence supporting the efﬁcacy of unicompartmental knee
arthroplasty (UKA) in patients with knee OA restricted to
a single compartment is summarised in a recent systematic
review of nine studies comparing UKA with TKA166. This
included one RCT167 (LoE Ib), six concurrent non-rando-
mised trials (LoE IIa) and two retrospective comparative
studies with historical controls (LoE III). Knee pain and func-
tion were comparable 5 years after UKA and TKA but range
of movement was better after UKA166. Complication rates
were similar following both procedures but prosthesis
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with >90% for TKA166.
23. Osteotomy and joint preserving surgical proce-
dures should be considered in young adults
with symptomatic hip OA, especially in the pres-
ence of dysplasia. For the young and physically
active patient with signiﬁcant symptoms from
unicompartmental knee OA, high tibial osteotomy
may offer an alternative intervention that delays
the need for joint replacement some 10 years.
SOR: 75% (95% CI 64e86)
Osteotomy is recommended as a modality of treatment in
10/10 existing guidelines for the management of hip or knee
OA where this was considered4. Intertrochanteric varus or
valgus osteotomy has been used as a treatment for hip
OA for nearly a century168 and pelvic or femoral osteoto-
mies are widely advocated to correct the biomechanics
and joint congruency in young patients with hip dysplasias
before the development of symptomatic hip OA169. Evi-
dence to support the efﬁcacy of these procedures is limited
to analysis of clinical outcomes in three uncontrolled pro-
spective170e172 and nine retrospective cohort studies63
(LoE III). High tibial osteotomy was promulgated as a treat-
ment for knee OA in the 1960s173. The biomechanical ratio-
nale for the operation, that realignment of the varus
deformity would reduce stress on the medial compartment
of the knee by redistributing the weight of the body from
the arthrotic medial compartment to the healthy lateral
one174, was challenged by a study that demonstrated that
while 25 of valgus angulation were required to unload the
medial compartment of the joint175 optimal clinical results
were associated with corrections of only 6e14176. The
proposition that high tibial osteotomy may offer an alterna-
tive intervention that can delay the need for joint replace-
ment for some 10 years is supported to some extent by
an MA of 2406 osteotomies in 19 uncontrolled cohort stud-
ies176 (LoE III). Good or excellent outcomes, deﬁned as less
pain and improved walking ability or >70 points on the Hos-
pital for Special Surgery (HSS) knee rating system177 were
achieved in 75% of patients at 60 months and 60% of pa-
tients at 100 months176. The overall failure rate at 10 years
was 25% but the average time between high tibial osteot-
omy and arthroplasty was 6 years176.
24. The roles of joint lavage and arthroscopic de-
bridement in knee OA are controversial. Although
some studies have demonstrated short-term
symptom relief, others suggest that improvement
in symptoms could be attributable to a placebo
effect.
SOR: 60% (95% CI 47e82)
Arthroscopic debridement, a procedure that variably in-
cludes joint lavage, the removal of loose bodies, debris,
mobile fragments of articular cartilage, unstable torn menisci
and impinging osteophytes, has been extensively used in
the treatment of OA knee for more than 70 years178; and joint
lavage is currently recommended as useful treatment for pa-
tients with knee OA in 3/3 treatment guidelines where this
modality of therapy was considered4. However, controversy
regarding the efﬁcacy and indications for these procedures
in the management of knee OA continues. For many years
evidence for the efﬁcacy of arthroscopic joint lavage and
debridement in knee OA rested on the clinical outcomes
observed in uncontrolled cohorts179e183 as is the case forthemajority of surgical interventions (LoE III). In such studies
50e80% of patients were typically recorded as having de-
creases in knee pain lasting from 1 to 5 years184. One
RCT, which compared articular debridement and lavage
alone in 76 knees with medial compartment knee OA, found
that 80% of the debridement group and 14% of the washout
group were pain free at 1 year, with 59% of the debridement
group and 12% of the washout group remaining free from
knee pain after 5 years185 (LoE Ib). A second prospective
comparative study compared arthroscopic debridement
with non-operative medical treatment in 70 patients186. After
2 years 75% of the operated patients and 16% of the medi-
cally treated patients had improvements using the HSS177
knee rating score186. RCTs comparing tidal knee irrigation
with standard medical therapy187, and joint lavage plus
physiotherapy with physiotherapy alone188 both demon-
strated statistically signiﬁcant reduction in pain in the lavage
groups at 3 months187,188, and this was still evident at 1 year
in the latter trial188 (LoE Ib). However a good quality, pla-
cebo-controlled RCT in which 180 patients with knee OA
were randomly assigned to receive arthroscopic debride-
ment, arthroscopic lavage or placebo (sham) surgery with
a skin incision and simulated arthroscopy showed no signif-
icant differences between the groups in the primary end
point (pain on a self-reported 12-item knee speciﬁc pain
scale) at 24 months, or in any of the other secondary out-
come measures of pain and function at any time point189.
The ESs for pain and function were 0.09 (95% CI 0.27,
0.44) and 0.10 (95% CI 0.45, 0.26) for arthroscopic la-
vage, and 0.01 (95% CI 0.37, 0.35) and 0.09 (95% CI
0.27, 0.45) for arthroscopic debridement. This is one of
only a very few placebo-controlled RCTs of surgical proce-
dures in which sham surgery has been undertaken. Clearly
surgery does have very powerful placebo effects and the in-
vestigators emphasised, as have others190, that the power of
placebos should never be underestimated. Although much
of the controversy that followed the publication of this study
related to the ethical and practical issues of undertaking
blinded placebo-controlled trials of surgical procedures, it
was also criticised on methodological grounds relating to
the design of the study, the documentation of clinical and op-
erative features, the outcome measures employed and the
statistical analysis191, as well as a failure to undertake a sub-
set analysis to see whether any subgroups of patients who
were deriving beneﬁt from arthroscopic debridement were
being lost in the pooled analysis. A recent review of pub-
lished studies concluded that there was some evidence to
suggest that arthroscopic debridement of meniscus tears
in patients with OA and arthroscopic debridement of knees
with low-grade OA may have limited utility192 (LoE III).
25. In patients with OA of the knee, joint fusion can
be considered as a salvage procedure when joint
replacement has failed.
SOR: 69% (95% CI 57e82)
The most common indication for knee arthrodesis in pa-
tients with knee OA is severe pain and instability in an unrec-
onstructable knee following an infection at the site of
a previous knee arthroplasty193. Although success rates
with primary and revision arthroplasty have improved con-
siderably in the last two decades knees with substantial
metaphyseal bone loss, inadequate ligamentous restraints,
multiple failed revisions, inadequate soft-tissue coverage
with loss of extensor mechanism and infection with virulent
organisms should also be considered193, as should patients
with serious medical co-morbid disease (LoE IV). Knee
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replacement has failed in both the existing guidelines that
considered this modality of treatment4. Evidence of out-
comes following knee arthrodesis is largely based on
information from uncontrolled retrospective cohort stud-
ies194e198 (LoE III). However a comprehensive review and
MA of studies published in 1995 reported successful fusions
in 94.6% of cases following intramedullary nailing compared
with 63.6% when external ﬁxators were used199. In one
small comparison of nine OA patients who had undergone
knee arthrodesis with nine who had had a primary TKA,
SF-36 scores for pain, health, vitality, social and emotional
well-being were similar in the two groups, although the ar-
throplasty treated patients scored higher for physical func-
tioning200. The Arthritis Impact Measurement Score (AIMS)
was also better after arthroplasty because of increased
mobility (0.97 vs 2.5 points) and physical activity (4 vs 6.3
points) but patients with an arthrodesis had a better mean
score on the pain scale (3.3 vs 3.9)200. In general following
knee arthrodesis patients can expect a stable painless leg
with some functional difﬁculties with climbing stairs and
with sitting in a theatre or an aeroplane193.
Contraindications to knee arthrodesis include an arthrod-
esis of the contralateral hip or knee and signiﬁcant OA in the
ipsilateral hip or ankle199. All patients can expect some
shortening of the leg (2.5e6.4 cm)193 and complications
may occur in up to 50% of patients. These include peroneal
nerve palsy, pain associated with migration of the metal
nail, thrombophlebitis and, rarely, non-union193.DiscussionSCOPE AND PURPOSEThe OARSI treatment guidelines have been developed to
provide evidence-based, expert consensus recommenda-
tions for the management of hip and knee OA, which are cur-
rent, patient-focussed, and globally relevant. Although their
primary purpose is to provide assistance to physiciansandal-
lied health care professionals in both general and specialist
practise, it is anticipated that the recommendations will also
provide an authoritative source of information about options
for the management of OA hip or knee for patients, and for
those involved in the funding and administration of health
care. It is also anticipated that these OARSI international
core recommendations will be modiﬁed and adapted as ap-
propriate for National and Regional application, and for use
by health care professionals in different specialist settings.
The systematic review of existing guidelines and recent
research evidence for the treatment of OA of the hip and/
or knee, which formed the ﬁrst part of the OARSI exercise,
identiﬁed a ‘core set’ of 20 treatment modalities which were
universally recommended in 23 evidence-based and/or ex-
pert consensus guidelines from around the world4. Critical
appraisal of these guidelines suggested that overall quality
was sub-optimal and that consensus recommendations
were not always supported by the best available clinical ev-
idence4. The appraisal suggested that there was a need for
updated guidelines; and that hybrid guidelines combining
expert opinion with research evidence were most likely to
fulﬁl high quality standards4,5. However the quality of such
hybrid guidelines ultimately reﬂects not only the quality of
the systematic review of the research evidence, but also
the experience, expertise and judgement of the experts
charged with producing them. It has been suggested that
treatment guideline development groups should be multidis-
ciplinary, and ideally should include representatives from allstakeholder groups whose professional activities or inter-
ests are under consideration12. In order to approach this re-
quirement the OARSI Treatment Guideline Committee was
made up of 16 experts from four medical disciplines (pri-
mary care 2, rheumatology 11, orthopaedic surgery 1 and
evidence-based medicine 2) from two continents and six
countries (Canada, France, Netherlands, UK and USA).
ACR guidelines for the medical management of OA of the
hip or knee201 were developed by four US rheumatologists,
and the most recent EULAR recommendations for the man-
agement of hip OA were developed by 23 experts from de-
partments of rheumatology and orthopaedics from 14
countries limited to Europe63. These and other existing
guidelines4 have been variously criticised for lack of meth-
odological rigour, editorial independence and applicability
as well as for inadequate stakeholder involvement202e204.
Details of the methodology for undertaking the systematic
search for existing guidelines, and the quality and content
assessment and data analyses that led to the critical ap-
praisal of the 23 existing guidelines have been presented
and discussed in detail in the ﬁrst part of this report4, as
have the methodological details of the systematic review
of the scientiﬁc evidence from 2002 to 2006 and the quality
and outcome assessments for efﬁcacy, side effects and
cost-effectiveness4. So too have the sensitivity analyses
that were undertaken to determine whether selected
RCTs published after January 31st 2006 would alter any
of the evidence-based conclusions from the critical ap-
praisal of existing guidelines and the systematic review of
the recent research evidence signiﬁcantly4.
A Delphi exercise was undertaken to generate consensus
recommendations. This followed the approach pioneered
during the development of theEULARguidelines for the treat-
ment of knee64 andhip63OAwith some important differences.
In the development of the EULAR recommendations expert
consensus on only 10 key treatment propositions, preceded
the systematic search for research evidence; a process that
we have characterised as clinically driven and evidence-
supported4. By contrast during thedevelopment of theOARSI
recommendations the results of the systematic review of the
research evidence and the critical appraisal of existing guide-
lines were made available to the guideline development
committee before they embarked on the Delphi exercise,
a process that we have characterised as evidence-driven
and clinically supported4. No restriction was placed on the
number of treatment propositions or recommendations to be
considered and eventual consensuswas reached on the rec-
ommendation of 25 carefully worded propositions after six
Delphi rounds. These treatment propositions encompass all
of the 20modalities of therapy which were universally recom-
mended in existing guidelines4(Table 4) and all but four of the
modalities of treatment for which there was agreement in
between 25% and 100% of existing guidelines4(Table 4).STAKEHOLDER CONSULTATIONStakeholder involvement is one of the key criteria in the
appraisal of clinical guidelines5. In order to obtain feedback
and suggestions from potential users of the recommenda-
tions during the process of guideline development two
consultation steps were included. Such consultation with
potential guideline users, which is, for example, always in-
cluded during the development of treatment guidelines by
the Scottish Intercollegiate Guidelines Network (SIGN)205,
serves to help generate a sense of involvement and owner-
ship among potential users as well as generating valuable
feedback and suggestions for the committee concerning
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ﬁrst of these consultation steps, described in detail in the
ﬁrst part of this report4, was a pilot survey of the perceived
usefulness of the treatment modalities addressed in existing
guidelines among physicians and other health care profes-
sionals attending a New York University e OARSI Rheuma-
tology Symposium in New York City in 2006. Although the
number of participants was small, the range of health pro-
fessionals limited and the majority of those surveyed were
from the USA, the views expressed concerning the useful-
ness of various modalities of treatment were found to be
consistent with those generated by the critical appraisal of
the existing guidelines that led to the deﬁnition of a core
set of recommended treatment modalities4. The second
and more comprehensive public consultation step was con-
ducted after four rounds of the Delphi exercise had generated
provisional consensus on 34 propositions. Thesewere posted
on theOARSIwebsite andpresented for comment anddiscus-
sion by OARSI members at a plenary session of the World
Congress on OA in Prague in December 2006. Suggestions
fromOARSI members were considered by the guideline com-
mitteeprior to further additions, amalgamations,minor reword-
ing and two ﬁnal Delphi rounds, which ultimately led to
consensus on the 25 carefully worded propositions.INTERPRETATION OF LOE, ES AND SORThe type of research evidence that is considered optimal
or admissible when undertaking systematic reviews varies
according to the type of clinical question that is being ad-
dressed. While a prospective cohort study may be the
most appropriate type of study to assess the importance
of a risk factor for disease causation or progression, RCTs
are regarded as the gold standard for assessing the efﬁcacy
of therapeutic interventions206. Evidence hierarchies, such
as the one used in this study (Table II), are recommended12,
and widely used, to grade the level of evidence during the
development of treatment guidelines. Such methods for
grading strength of recommendations are however, prob-
lematic. Although they do allow guideline developers to in-
clude consideration of the research evidence, they are
strongly driven by the evidence hierarchy for efﬁcacy and al-
ways downgrade highly effective treatments such as total
joint replacements, which are not readily assessable by
RCT, because of practical and ethical considerations. To
overcome this problem, the EULAR OA task force64,210
and a multidisciplinary UK panel211 developed an integrated
approach in which SOR, based on both the LoE and clinical
expertise is recorded on a VAS64,211. This approach, which
was adopted in the development of the OARSI recommen-
dations, allows decision-making based on the balance be-
tween research evidence and clinical practise, so that the
SOR reﬂects the overall clinical effectiveness of the therapy
in question. Secondly, SORs which are predominantly based
on an evidence hierarchy for clinical efficacy may not ade-
quately encompass adverse effects or truly reﬂect the
trade-off between risk and beneﬁt which is fundamental for
making clinical decisions. In addition, traditionally graded
SORs are recorded on categorical scales12,207e209. The
use of a VAS based SOR64,211 has the advantage of allow-
ing the calculation of 95% CIs as well as mean values, so
enabling users to better estimate the precision of the SOR
for any particular recommendation.
The value of using the VAS SOR with 95%CI to reﬂect the
balance between research evidence and clinical expertise is
well illustrated in two of the OARSI recommendations. The
SOR for joint replacement in patients with hip and kneeOA (proposition 21) was 96% with very narrow 95% CI
(94e98) despite only grade III research evidence, reﬂecting
the excellent trade-off between harms and beneﬁts for these
procedures, and the strong consensus among the experts.
By contrast the SOR for IA injections of hyaluronate in pa-
tients with OA knee or hip (proposition17) was only 64%
with wide 95% CI (43e85), despite Ia evidence for efﬁcacy
of pain relief from some published metaanalyses. Presum-
ably this reﬂected a range of expert opinion as a conse-
quence of conﬂicting evidence of efﬁcacy in RCTs and
MAs of this modality of therapy, as well as consideration of
the cost, convenience and overall risk/beneﬁt ratio.
Effect size is a measure of standard mean difference be-
tween treatments (e.g., treatment vs placebo) in units of the
SD of the difference212. When conducting MAs it is common
practise to normalise the same, or different outcome mea-
sures, across different studies. This allows cross-study com-
parisons and statistical pooling of the results from different
studies. However, ES is a derived outcome developed for
research purposes which reﬂects change as an SD of
change, but lacks the numerical measurement of the out-
come that was actually assessed (e.g., % pain reduction on
a 0e100 mm VAS). Unlike outcome measures themselves
or the NNT, the interpretation of ES in clinical practise is
not an easy one to communicate clearly to health administra-
tors, health professionals or patients. Great care must be
taken when attempting to compare ES across treatments,
e.g., electromagnetic therapy (ES¼ 0.77, 95% CI 0.36,
1.17) vs NSAIDs (ES¼ 0.32, 95% CI 0.24, 0.39) for osteoar-
thritic pain4. Conclusions based on such comparisons of ES
may be dangerous and invalid without further examination of
someof the details of the studies, such as the number of stud-
ies included in the MAs, the characteristics of the patients in-
cluded and the comparators that have been used. Potential
users of the OARSI guidelines are, therefore, strongly
advised to examine the 95% CIs between treatments before
coming to any conclusions about comparisons of ESs.THE CONCEPT OF A CORE SET OF RECOMMENDATIONS:
COMPARISON WITH OTHER GUIDELINESAttempts have been made to deﬁne core sets for OA213
within the International Classiﬁcation of Functioning, Disabil-
ity and Health (ICF)214 and an International Classiﬁcation of
Health Interventions has been proposed by theWorld Health
Organisation (WHO)215. There are, however, currently no
generally accepted core sets of treatments for patients with
OA. In the ﬁrst part of this report we were able to identify 20
modalities of therapy for OA hip and/or knee which were uni-
versally recommended in existing guidelines4. These com-
prised eight non-pharmacological modalities (education,
self-management, regular telephone contact, aerobic, mus-
cle strengthening and water-based exercises, referral to
a physical therapist and the use of a cane or stick); six phar-
macological modalities (acetaminophen, NSAIDs, both non-
selective with co-prescription of a PPI or misoprostol and
selective COX-2 inhibitors, opioids and herbal preparations);
ﬁve surgical modalities (total joint replacements, osteotomy,
knee fusion and knee aspiration/joint lavage) as well as the
combination of non-pharmacological and pharmacological
treatments. With some carefully worded caveats all of these
modalities of therapy are included in the current OARSI rec-
ommendations which have been developed by a multina-
tional, multidisciplinary group of experts from primary and
secondary care after evaluation of the critical appraisal of
existing treatment guidelines and a systematic review of the
recent research evidence, with the exception of herbal
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treatment recommendations, with caveats, based on four
non-phamacological modalities (weight loss, shoe insoles,
knee braces, TENs), four pharmacological (oral and topical
NSAIDs, topical capsaicin and IA injections of corticosteroids
and hyaluronate) and one surgical modality (arthroscopic
debridement) which are recommended in 75% of existing
guidelines; for acupuncture, thermal modalities and glucos-
amine sulphate recommended in 50%, and for chondroitin
sulphate recommended in 25%. However, the SOR was
only >90% in 8/25 of the carefully worded treatment proposi-
tions relating toﬁvenon-pharmacologicalmodalitiesof therapy
(education/self-help, exercise, weight reduction and the use of
walkingaids); onepharmacologicalmodality (acetaminophen)
andone surgicalmodality of treatment (total joint replacement)
in addition to the general recommendation to combine
pharmacological and non-pharmacological treatments.LIMITATIONSThe OARSI guidelines have some limitations. Although
the guideline development committee was multinational
and multidisciplinary it only included experts from Europe
and North America and 11/16 of its members were rheuma-
tologists. Primary care physicians and orthopaedic sur-
geons were underrepresented. Although there were no
experts from allied health professions such as nursing or
physiotherapy, efforts were made to obtain the views of
other health professionals through the questionnaire survey
at the New York e OARSI Symposium and the collection of
comments from the wider OARSI membership through
posting the draft recommendations on the OARSI website
and public presentation and discussion of the draft guide-
lines at the World Congress on OA in December 2006. Un-
fortunately patients’ perspectives on the recommendations
remain unknown. Secondly, due to time constraints, only
the scientiﬁc literature from 2002 to 2006 was systematically
reviewed. Evidence before 2002 was obtained from the
EULAR systematic review, and it was not possible to com-
bine the data from the two systematic reviews because ofTable V
Research evidence for efficacy of modalities of ther
Modality Frequency of recommendation
in other guidelines
Non-pharmacological
Spa/sauna 1 Guideline only
Laser 1 of 6
Ultrasound 1 of 5
Radiotherapy 1 Guideline only
Electrotherapy/EMG 1 of 8
Pharmacological
Diacerein 1 of 2
SAM-e e
ASU 3 of 4
Herbal remedy e
Oestrogen 1 Guideline only
Bisphosphonates e
Antidepressants 1 Guideline only
Surgical
Patellar resurfacing 1 Guideline only
Joint distraction e
Knee aspiration e
ES¼ 0.2 is considered small, ES¼ 0.5 is moderate, and ES> 0.8 is lar
Ib: RCT; IIa: controlled study without randomisation; IIb: quasi-experimen
observational studies (e.g., caseecontrol, cohort, cross-sectional studiesdiscrepancies in methodology and the scope of the guide-
lines. Thirdly, a number of new studies have been published
after the closing date of our literature search (Jan 2006).
These include some studies of chondroitin sulphate131,133,
weight reduction39, diacerein137,216 and vascular risk of
NSAIDs and coxibs87,217e219. Whether any of this more re-
cently published data would change the calculated evi-
dence parameters signiﬁcantly and whether they will have
any impact on the current OARSI recommendations re-
mains to be determined. Finally, the Delphi exercise had
to be arbitrarily terminated after the sixth round when it
had become clear that consensus to accept or reject two
propositions [one for diacerein and the other for avocado-
soybean unsaponiﬁables (ASU)] was not possible despite
attempts at rewording or amalgamation with treatment prop-
ositions that had already been accepted. There was limited
support (>20% but <60% voting) for propositions stating
that diacerein and ASU may provide slow acting symptom-
atic beneﬁt in patients with knee or hip OA.
The evidence for symptomatic efﬁcacy of diacerein in pa-
tients with OA hip or knee available to the OARSI Treatment
GuidelinesDevelopment group from the systematic review of
the research evidence from 2002 to January 2006 came from
four RCTs with heterogeneous results138,220e222 (LoE Ib).
The ESpain was small (0.22, 95% CI 0.01, 0.42) and the RR
for diarrhoeawas 3.98 (95%CI 2.90, 5.47)4. Some symptom-
atic efﬁcacy of diacerein was suggested by a more recently
published RCT223 and two MAs137,216, but the ﬁrst of these
raised concerns about the heterogeneity of outcomes and
the possibility of publication bias137, and the latter216 was
criticised for omitting the results of analyses for heterogeneity
and for possible bias resulting from industry support224.
The evidence for symptomatic efﬁcacy of ASU in patients
with OA hip or knee available to the OARSI Treatment
Guidelines Development group from the systematic review
of the research evidence from 2002 to January 2006
came from a systematic review of four RCTs, three out of
four of which showed some evidence of efﬁcacy for relief
of pain in OA hip and knee225 (LoE 1a) and treatment
with ASU was recommended in 3/4 existing guidelines4.apy not included in OARSI recommendations
LoE Research evidence
ESpain (95% CI)
Ib 0.46 (0.17, 0.75)
Ia e
Ia 0.06 (0.39, 0.52)
IIb e
Ia 0.77 (0.36, 1.17)
Ib 0.22 (0.01, 0.42)
Ia 0.22 (0.25, 0.69)
Ia e
Ia e
IV e
IV e
IV e
Ib e
IV e
IV e
ge. SAM-e: S-adenosylmethionine. LoE: Ia: meta-analysis of RCTs;
tal study (e.g., uncontrolled trial, one arm dose-response trial,); III:
); and IV: expert opinion.
155Osteoarthritis and Cartilage Vol. 16, No. 2Other modalities of therapy for hip and/or knee OA for
which there is some published suggestion of efﬁcacy, but
for which no current recommendations are made in the
OARSI guidelines are listed in Table V together with the
LoE for efﬁcacy, the ES (95% CI) where this could be calcu-
lated and the frequency with which the therapeutic modality
is recommended in other guidelines.UTILITY AND APPLICABILITYAppendix 1. Members of the OARSI treatment guide-
lines committee
Chair George Nuki, Queen’s Medical Research
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Edinburgh, UK
Co-chair Roland W. Moskowitz, University Hospi-
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Nottingham City Hospital, University of
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Medicine, New York, NY, USAThese are OARSI international core recommendations
for the treatment of OA of the hip and knee. It is anticipated
that they will need to be adapted, and possibly modiﬁed, for
National and Regional application, where individual modal-
ities of therapy are not available or where there are other
organisational barriers to introducing the core recommenda-
tions into primary care and specialist practise. In order to
facilitate dissemination and implementation the guideline
development committee recommends
 Publication of the guidelines in Osteoarthritis and Carti-
lage accompanied by a commentary to assist with
interpretation.
 Delivery of the document to all OARSI members with
encouragement to translate the guidelines into different
languages.
 Posting the guidelines with open access on the public
section of the OARSI website.
 Fostering contact and liaison with other societies and
professional groups representing stakeholders in pri-
mary and secondary care worldwide.
 Encouraging other professional and multidisciplinary
groups concerned with the management of patients
with OA knee and hip in primary and secondary care
settings throughout the world to consider using the
OARSI recommendations as a starting point for devel-
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implementation of the guidelines on clinical outcomes.Peter Croft, Keele University, Keele, UK
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ogy, Nottingham City Hospital, University
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France
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Stefan Lohmander, Department of Ortho-
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Peter Tugwell, Institute of Population
Health, University of Ottawa, Ottawa,
CanadaOARSI plans to update research evidence annually and
the guidelines as appropriate every 3e5 years.
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